{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:28:47Z","timestamp":1782833327334,"version":"3.54.5"},"reference-count":67,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007365","name":"Fondazione IRCCS Policlinico San Matteo","doi-asserted-by":"publisher","award":["20180104754"],"award-info":[{"award-number":["20180104754"]}],"id":[{"id":"10.13039\/100007365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The process of metastatic dissemination begins when malignant cells start to migrate and leave the primary mass. It is now known that neoplastic progression is associated with a combination of genetic and epigenetic events. Cancer is a genetic disease and this pathogenic concept is the basis for a new classification of tumours, based precisely on the presence of definite genetic lesions to which the clones are addicted. Regarding the scatter factor receptors MET and Recepteur d\u2019Origin Nantais (RON), it is recognised that MET is an oncogene necessary for a narrow subset of tumours (MET-addicted) while it works as an adjuvant metastogene for many others. This notion highlights that the anti-MET therapy can be effective as the first line of intervention in only a few MET-addicted cases, while it is certainly more relevant to block MET in cases of advanced neoplasia that exploit the activation of the invasive growth program to promote dissemination in other body parts. Few data are instead related to the role played by RON, a receptor homologous to MET. We have already demonstrated an implication of MET and RON genes in brain metastases from lung cancer. On this basis, the aim of this work is to recapitulate and dissect the molecular basis of metastatic brain dissemination from lung cancer. The latter is among the big killers and frequently gives rise to brain metastases, most often discovered at diagnosis. Molecular mechanisms leading to tumour spread to the brain are mostly unknown and in turn these tragic cases are still lacking effective therapies. Based on previously published data from our group, we aim to summarise and analyse the pathogenic mechanisms leading to activation of the scatter factor receptor in brain metastatic lesions of lung primaries, from the point of view of replacing the currently used empirical treatment with a more targeted approach.<\/jats:p>","DOI":"10.3390\/cancers11030271","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T11:00:44Z","timestamp":1551178844000},"page":"271","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Brain Metastases from Lung Cancer: Is MET an Actionable Target?"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0929-4394","authenticated-orcid":false,"given":"Giulia","family":"Stella","sequence":"first","affiliation":[{"name":"Department of Medical Sciences and Infectious Diseases, Unit of Respiratory System Diseases, IRCCS Fondazione Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Corino","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Infectious Diseases, Unit of Respiratory System Diseases, IRCCS Fondazione Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Berzero","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Casimiro Mondino, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kolling","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Infectious Diseases, Unit of Respiratory System Diseases, IRCCS Fondazione Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7159-7869","authenticated-orcid":false,"given":"Andrea","family":"Filippi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Infectious Diseases, Unit of Radiation Therapy, IRCCS Fondazione Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Benvenuti","sequence":"additional","affiliation":[{"name":"Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo TO, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1586\/17476348.2015.1083428","article-title":"Classification of Different Patterns of Pulmonary Adenocarcinomas","volume":"9","author":"Truini","year":"2015","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JCO.2006.06.8015","article-title":"Lung Cancer in Never Smokers: A Review","volume":"25","author":"Subramanian","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/1097-0142(19851015)56:8<2107::AID-CNCR2820560837>3.0.CO;2-T","article-title":"Presenting Conditions of 1539 Population-Based Lung Cancer Patients by Cell Type and Stage in New Hampshire and Vermont","volume":"56","author":"Chute","year":"1985","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0360-3016(98)00442-8","article-title":"Identification of Prognostic Factors in Patients with Brain Metastases: A Review of 1292 Patients","volume":"43","author":"Lagerwaard","year":"1999","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","article-title":"Recursive Partitioning Analysis (RPA) of Prognostic Factors in Three Radiation Therapy Oncology Group (RTOG) Brain Metastases Trials","volume":"37","author":"Gaspar","year":"1997","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_7","first-page":"357","article-title":"Stereotactic Radiosurgery of Brain Metastases","volume":"60","author":"Specht","year":"2016","journal-title":"J. Neurosurg. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.7150\/ijbs.28608","article-title":"Comparison of Prognostic Indices in NSCLC Patients with Brain Metastases after Radiosurgery","volume":"14","author":"Gao","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-009-0057-4","article-title":"The role of steroids in the management of brain metastases: A systematic review and evidence-based clinical practice guideline","volume":"96","author":"Ryken","year":"2010","journal-title":"J. Neuro-Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e000262","DOI":"10.1136\/esmoopen-2017-000262","article-title":"Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: Summary of a multidisciplinary roundtable discussion","volume":"3","author":"Preusser","year":"2018","journal-title":"ESMO Open"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10555-016-9618-0","article-title":"Progression and metastasis of lung cancer","volume":"35","author":"Popper","year":"2016","journal-title":"Cancer Metast. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrm3012","article-title":"MET signalling: Principles and functions in development, organ regeneration and cancer","volume":"11","author":"Trusolino","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","article-title":"Known and novel roles of the MET oncogene in cancer: A coherent approach to targeted therapy","volume":"18","author":"Comoglio","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1101\/sqb.2016.81.031377","article-title":"RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers","volume":"81","author":"Faham","year":"2016","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nrc3545","article-title":"MSP-RON signalling in cancer: Pathogenesis and therapeutic potential","volume":"13","author":"Yao","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2012). Comprehensive genomic characterization of squamous cell lung cancers. Nature, 489, 519\u2013525.","DOI":"10.1038\/nature11404"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2014). Comprehensive molecular profiling of lung adenocarcinoma. Nature, 511, 543\u2013550.","DOI":"10.1038\/nature13385"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3390\/cancers6031540","article-title":"Targeting MET Amplification as a New Oncogenic Driver","volume":"6","author":"Kawakami","year":"2014","journal-title":"Cancers"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"Bean","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2018.02.007","article-title":"Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib","volume":"118","author":"Wang","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1158\/2159-8290.CD-16-1181","article-title":"Oncogenic MET as an Effective Therapeutic Target in Non-Small Cell Lung Cancer Resistant to EGFR Inhibitors: The Rise of the Phoenix","volume":"6","author":"Trusolino","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated with Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2017.04.031","article-title":"MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values","volume":"12","author":"Lee","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/13543784.2018.1462336","article-title":"C-MET inhibitors for advanced non-small cell lung cancer","volume":"27","author":"Pasquini","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2016.11.011","article-title":"The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable","volume":"103","author":"Reungwetwattana","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2017.09.006","article-title":"Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping","volume":"113","author":"Zhang","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Suzawa, K., Offin, M., Lu, D., Kurzatkowski, C., Vojnic, M., Smith, R.S., Sabari, J.K., Tai, H., Mattar, M., and Khodos, I. (2018). Activation of KRAS mediates resistance to targeted therapy in MET exon 14 mutant non-small cell lung cancer. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-18-1640"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1016\/j.jtho.2018.02.030","article-title":"Novel MET Exon 14 Skipping Treatment-Na\u00efve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib","volume":"13","author":"Jiang","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1082596","article-title":"Mutational analysis of the tyrosine kinome in colorectal cancers","volume":"300","author":"Bardelli","year":"2003","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/neuonc\/nov325","article-title":"MET mutations are associated with aggressive and radioresistant brain metastatic non-small-cell lung cancer","volume":"18","author":"Stella","year":"2016","journal-title":"Neuro-Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Milan, M., Benvenuti, S., Balderacchi, A.M., Virz\u00ec, A.R., Gentile, A., Senetta, R., Cassoni, P., Comoglio, P.M., and Stella, G.M. (2018). RON tyrosine kinase mutations in brain metastases from lung cancer. ERJ Open Res., 4.","DOI":"10.1183\/23120541.00083-2017"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.sbi.2004.10.010","article-title":"The sema domain","volume":"14","author":"Gherardi","year":"2004","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ccr.2004.06.013","article-title":"The Sema domain of Met is necessary for receptor dimerization and activation","volume":"6","author":"Stamos","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/humu.21374","article-title":"MET mutations in cancers of unknown primary origin (CUPs)","volume":"32","author":"Stella","year":"2011","journal-title":"Hum. Mutat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrc822","article-title":"Epithelial-mesenchymal transitions in tumour progression","volume":"2","author":"Thiery","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/scbi.2000.0366","article-title":"Scatter factors and invasive growth","volume":"11","author":"Comoglio","year":"2001","journal-title":"Semin. Cancer Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ebiom.2017.09.025","article-title":"MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin","volume":"24","author":"Stella","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcdb.2015.01.002","article-title":"Anatomy and physiology of the blood-brain barrier","volume":"38","author":"Serlin","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00018-015-2050-8","article-title":"Factors controlling permeability of the blood-brain barrier","volume":"73","author":"Almutairi","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_46","first-page":"11","article-title":"Pathways for small molecule delivery to the central nervous system across the blood-brain barrier","volume":"6","author":"Mikitsh","year":"2014","journal-title":"Perspect. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8267","DOI":"10.1038\/s41598-018-26636-6","article-title":"Metastatic Brain Tumors Disrupt the Blood-Brain Barrier and Alter Lipid Metabolism by Inhibiting Expression of the Endothelial Cell Fatty Acid Transporter Mfsd2a","volume":"8","author":"Tiwary","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1158\/0008-5472.CAN-15-3541","article-title":"Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer","volume":"76","author":"Xing","year":"2016","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2015.64.7685","article-title":"Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients with Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses","volume":"35","author":"Cloughesy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1158\/1078-0432.CCR-17-0782","article-title":"Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors","volume":"23","author":"Poulsen","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Wang, J., Goetsch, L., Tucker, L., Zhang, Q., Gonzalez, A., Vaidya, K.S., Oleksijew, A., Boghaert, E., Song, M., and Sokolova, I. (2016). Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2138-z"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1158\/0008-5472.CAN-16-0026","article-title":"Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors","volume":"76","author":"Yang","year":"2016","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s13256-018-1875-9","article-title":"Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: Two case reports","volume":"12","author":"Moriceau","year":"2018","journal-title":"J. Med. Case Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jtho.2016.09.127","article-title":"Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases","volume":"12","author":"Klempner","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"183","DOI":"10.20892\/j.issn.2095-3941.2017.0017","article-title":"Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer: A case report","volume":"14","author":"Wang","year":"2017","journal-title":"Cancer Biol. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-17-1192","article-title":"Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models","volume":"23","author":"Engstrom","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1093\/annonc\/mdx396","article-title":"Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)","volume":"28","author":"Felip","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1158\/0008-5472.CAN-12-3775","article-title":"EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis","volume":"73","author":"Breindel","year":"2013","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1541-7786.MCR-15-0506","article-title":"Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer","volume":"14","author":"Kim","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1158\/1535-7163.MCT-14-1105","article-title":"Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2","volume":"14","author":"Smith","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.cell.2018.09.038","article-title":"Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor","volume":"175","author":"Hu","year":"2018","journal-title":"Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.immuni.2017.09.012","article-title":"Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy","volume":"47","author":"Glodde","year":"2017","journal-title":"Immunity"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Papaccio, F., Della Corte, C.M., Viscardi, G., Di Liello, R., Esposito, G., Sparano, F., Ciardiello, F., and Morgillo, F. (2018). HGF\/MET and the Immune System: Relevance for Cancer Immunotherapy. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113595"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/biomedicines3010138","article-title":"HGF\/Met-Signaling Contributes to Immune Regulation by Modulating Tolerogenic and Motogenic Properties of Dendritic Cells","volume":"3","author":"Hieronymus","year":"2015","journal-title":"Biomedicines"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.4049\/jimmunol.1200729","article-title":"The HGF Receptor\/Met Tyrosine Kinase Is a Key Regulator of Dendritic Cell Migration in Skin Immunity","volume":"189","author":"Baek","year":"2012","journal-title":"J. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/labinvest.2012.180","article-title":"Radiosensitization of brain metastasis by targeting c-MET","volume":"93","author":"Yang","year":"2013","journal-title":"Lab. Investig."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/jnci\/djr093","article-title":"Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer","volume":"103","author":"Luraghi","year":"2011","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/3\/271\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:34:42Z","timestamp":1760186082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/3\/271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":67,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["cancers11030271"],"URL":"https:\/\/doi.org\/10.3390\/cancers11030271","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]}}}